Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11254127 | 0.99 | HDAC3 (0.60) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| Bromide SCHEMBL7141567 | 0.99 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| Bromide SCHEMBL11248133 | 0.97 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3615155 | 0.86 | ALOX5 (0.51) | ABL1VCPNPC1RAB9AALDH1A1 | |
| SCHEMBL11090239 | 0.86 | MAPT (0.51) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3602570 | 0.86 | ABL1 (0.67) | ROCK1ABL1ROCK2VCPNPC1 | |
| SCHEMBL11239265 | 0.86 | MAPT (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL3606891 | 0.85 | ABL1 (0.68) | ABL1ALDH1A1SMN1; SMN2GSTO1MAPT | |
| SCHEMBL3604035 | 0.85 | ATP4A (0.56) | HDAC6ROCK1ABL1ROCK2VCP | |
| SCHEMBL30660070 | 0.85 | MEN1 (0.61) | HDAC3HDAC1HDAC2HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-1716127-B1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2380885-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-4548944-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1985-10-22 | — | — | US | disclosed |
| EP-0089730-A2 | Guanidino heterocyclicphenylamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
| EP-0073971-A1 | Thiadiazole oxides as gastric antisecretory agents | MERCK & CO. INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| EP-0059903-A1 | Diaminooxadiazoles, their use as gastric secretion inhibitors, and process for their preparation | MERCK & CO. INC. (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4315009-A | Antisecretory guanidine derivatives and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-02-09 | — | — | US | disclosed |
| EP-0003640-B1 | ANTISECRETORY GUANIDINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-01-27 | — | — | EP | disclosed |
| EP-0040696-A2 | Aminothiadiazoles as gastric secretion inhibitors | MERCK & CO. INC. (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0003640-A2 | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | HDAC3 4792/4885HDAC1 4592/4885HDAC2 4666/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | HDAC3 4763/4885HDAC1 4515/4885HDAC2 4622/4885 |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | HDAC3 3023/4885HDAC1 1788/4885HDAC2 1703/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | HDAC3 4792/4885HDAC1 4592/4885HDAC2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.